{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:46:09Z","timestamp":1787697969631,"version":"build-2784847793"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118730","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:52:42Z","timestamp":1761976362000},"page":"118730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ruthenium-based drugs as cancer stem cell inhibitors"],"prefix":"10.1016","volume":"193","author":[{"given":"Ingrid R.S.B.","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-2063","authenticated-orcid":false,"given":"Daniel P.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.biopha.2025.118730_bib2","doi-asserted-by":"crossref","first-page":"e1700","DOI":"10.1016\/S2214-109X(23)00406-0","article-title":"Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study","volume":"11","author":"Frick","year":"2023","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12935-024-03558-0","article-title":"Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy","volume":"24","author":"Mengistu","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118730_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2025.118730_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: the first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118730_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115323","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani","year":"2022","journal-title":"Biochem Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118730_bib9","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/pharmaceutics15122750","article-title":"Research progress of metal anticancer drugs","volume":"15","author":"Bai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118730_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116211","article-title":"A review on metal complexes and its anti-cancer activities: recent updates from in vivo studies","volume":"171","author":"Adhikari","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"41","key":"10.1016\/j.biopha.2025.118730_bib11","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1039\/D1DT02909F","article-title":"Metal complexes against breast cancer stem cells","volume":"50","author":"Li","year":"2021","journal-title":"Dalton Trans."},{"issue":"7","key":"10.1016\/j.biopha.2025.118730_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/pharmaceutics17070931","article-title":"Preclinical trials of cancer stem cells targeted by metal-based coordination complexes: a systematic review","volume":"17","author":"Bezerra","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118730_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9653244","article-title":"Cancer stem cells: from an insight into the basics to recent advances and therapeutic targeting","volume":"2022","author":"Bisht","year":"2022","journal-title":"Stem Cells Int"},{"issue":"6464","key":"10.1016\/j.biopha.2025.118730_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2025.118730_bib15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118730_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123015","article-title":"Cancer stem cell markers: symphonic masters of chemoresistance and immune evasion","volume":"355","author":"Sarabia-S\u00e1nchez","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2025.118730_bib17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tips.2023.11.006","article-title":"Biomarkers and targeted therapy for cancer stem cells","volume":"45","author":"Liu","year":"2024","journal-title":"Trends Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118730_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2005.08.020","article-title":"Core transcriptional regulatory circuitry in human embryonic stem cells","volume":"122","author":"Boyer","year":"2005","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.biopha.2025.118730_bib20","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1038\/s41388-019-0712-y","article-title":"The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance","volume":"38","author":"Hepburn","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118730_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2022.12.010","article-title":"Transcriptional factors targeting in cancer stem cells for tumor modulation","volume":"88","author":"Chaudhary","year":"2023","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13046-024-03021-y","article-title":"Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies","volume":"43","author":"Zhang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"Pt 3","key":"10.1016\/j.biopha.2025.118730_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2022.07.009","article-title":"Dysregulated FOXM1 signaling in the regulation of cancer stem cells","volume":"86","author":"Sher","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118730_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103277","article-title":"Cell signaling pathways as molecular targets to eliminate AML stem cells","volume":"160","author":"Rodrigues","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118730_bib26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cac2.12235","article-title":"Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells","volume":"41","author":"Silva","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib27","article-title":"Translational drugs targeting cancer stem cells in triple-negative breast cancer","volume":"33","author":"Oliveira","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41419-025-07983-5","article-title":"Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors","volume":"16","author":"Neves","year":"2025","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.biopha.2025.118730_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70406","article-title":"Cancer stem cells: bridging microenvironmental interactions and clinical therapy","volume":"15","author":"Wang","year":"2025","journal-title":"Clin. Transl. Med"},{"issue":"9","key":"10.1016\/j.biopha.2025.118730_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib33","article-title":"Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting","volume":"11","author":"Guo","year":"2023","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1186\/s12967-023-04575-9","article-title":"Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2025.118730_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jare.2024.06.014","article-title":"Tumor microenvironment as niche constructed by cancer stem cells: breaking the ecosystem to combat cancer","volume":"71","author":"Zhong","year":"2025","journal-title":"J. Adv. Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-023-01748-4","article-title":"Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118730_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.02.022","article-title":"PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways","volume":"450","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.biopha.2025.118730_bib39","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1039\/c3dt32214a","article-title":"Ruthenium complexes in different oxidation states: synthesis, crystal structure, spectra and redox properties","volume":"42","author":"Jab\u0142o\u0144ska-Wawrzycka","year":"2013","journal-title":"Dalton Trans."},{"key":"10.1016\/j.biopha.2025.118730_bib40","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.2147\/DDDT.S275007","article-title":"Ruthenium complexes as anticancer agents: a brief history and perspectives","volume":"14","author":"Lee","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118730_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.32604\/or.2024.057019","article-title":"Metal-based molecules in the treatment of cancer: from bench to bedside","volume":"33","author":"Bernal","year":"2025","journal-title":"Oncol. Res"},{"key":"10.1016\/j.biopha.2025.118730_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.214129","article-title":"Targeting translation: a promising strategy for anticancer metallodrugs","volume":"446","author":"Ortega","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.biopha.2025.118730_bib43","first-page":"231","article-title":"Oncological implication of the chemistry of ruthenium","volume":"11","author":"Clarke","year":"1980","journal-title":"Met Ions Biol. Syst."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-2797(83)90037-6","article-title":"Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma","volume":"45","author":"Sava","year":"1983","journal-title":"Chem. Biol. Inter."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00001813-199901000-00016","article-title":"Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors","volume":"10","author":"Sava","year":"1999","journal-title":"Anticancer Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2025.118730_bib46","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest N. Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2025.118730_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CAD.0b013e328322fbc5","article-title":"Central European Society for Anticancer Drug Research-EWIV. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study","volume":"20","author":"Lentz","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5414\/CPP47058","article-title":"Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]\/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors","volume":"47","author":"Henke","year":"2009","journal-title":"Int J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118730_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000154","article-title":"Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort","volume":"1","author":"Burris","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118730_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.euros.2022.04.015","article-title":"A phase 1b clinical study of intravesical photodynamic therapy in patients with bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"41","author":"Kulkarni","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"issue":"38","key":"10.1016\/j.biopha.2025.118730_bib52","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1021\/bi00038a034","article-title":"Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes","volume":"34","author":"Nov\u00e1kov\u00e1","year":"1995","journal-title":"Biochemistry"},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118730_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0162-0134(02)00543-3","article-title":"DNA binding studies of ruthenium(II) complexes containing asymmetric tridentate ligands","volume":"92","author":"Chao","year":"2002","journal-title":"J. Inorg. Biochem"},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118730_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-0134(02)00577-9","article-title":"Syntheses, characterization and DNA-binding studies of ruthenium(II) terpyridine complexes: [Ru(tpy)(PHBI)]2+ and [Ru(tpy)(PHNI)]2+","volume":"93","author":"Jiang","year":"2003","journal-title":"J. Inorg. Biochem"},{"issue":"7","key":"10.1016\/j.biopha.2025.118730_bib55","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00775-017-1479-7","article-title":"Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA\/protein binding, lipophilicity and anticancer activity","volume":"22","author":"\u010canovi\u0107","year":"2017","journal-title":"J. Biol. Inorg. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib56","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/chem.201704403","article-title":"Interfering with DNA high-order structures using chiral ruthenium(II) complexes","volume":"24","author":"Zou","year":"2018","journal-title":"Chemistry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118730_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-017-0104-6","article-title":"A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1\/2-mediated apoptosis in HepG2 cells through a p53-independent pathway","volume":"9","author":"Carvalho","year":"2018","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.biopha.2025.118730_bib58","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3389\/fonc.2019.00562","article-title":"Ruthenium complexes containing heterocyclic thioamidates trigger caspase-mediated apoptosis through MAPK signaling in human hepatocellular carcinoma cells","volume":"9","author":"Neves","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118730_bib59","article-title":"Chemistry and reactivity of ruthenium(II) complexes: DNA\/protein binding mode and anticancer activity are related to the complex structure","volume":"398","author":"Simovi\u0107","year":"2019","journal-title":"Coord. Chem. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118730_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/cplu.202400621","article-title":"Half-sandwich organometallic Ir(III) and Ru(II) compounds and their interactions with biomolecules","volume":"90","author":"Kozie\u0142","year":"2025","journal-title":"Chempluschem"},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1039\/C7MD00532F","article-title":"Synthesis, characterization and biological evaluation of six highly cytotoxic ruthenium(ii) complexes with 4\u2032-substituted-2,2\u2032:6\u2032,2''-terpyridine","volume":"9","author":"Qin","year":"2018","journal-title":"Medchemcomm"},{"issue":"6","key":"10.1016\/j.biopha.2025.118730_bib62","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/acsmedchemlett.9b00098","article-title":"High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2\u2032-Benzimidazolyl)-7-fluoro-coumarin","volume":"10","author":"Qin","year":"2019","journal-title":"ACS Med Chem. Lett."},{"issue":"16","key":"10.1016\/j.biopha.2025.118730_bib63","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1039\/C9DT00866G","article-title":"Discovery of high in vitro and in vivo antitumor activities of organometallic ruthenium(ii)-arene complexes with 5,7-dihalogenated-2-methyl-8-quinolinol","volume":"48","author":"Meng","year":"2019","journal-title":"Dalton Trans."},{"issue":"18","key":"10.1016\/j.biopha.2025.118730_bib64","doi-asserted-by":"crossref","first-page":"14174","DOI":"10.1021\/acs.inorgchem.1c01539","article-title":"Ruthenium(II) diphosphine complexes with mercapto ligands that inhibit topoisomerase IB and suppress tumor growth in vivo","volume":"60","author":"Silva","year":"2021","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.biopha.2025.118730_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112295","article-title":"Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis","volume":"246","author":"Tang","year":"2023","journal-title":"J. Inorg. Biochem"},{"issue":"27","key":"10.1016\/j.biopha.2025.118730_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202402028","article-title":"Bithiophene-functionalized infrared two-photon absorption metal complexes as single-molecule platforms for synergistic photodynamic, photothermal, and chemotherapy","volume":"63","author":"Li","year":"2024","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"3","key":"10.1016\/j.biopha.2025.118730_bib67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10637-016-0337-8","article-title":"Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines","volume":"34","author":"Flocke","year":"2016","journal-title":"Invest N. Drugs"},{"issue":"61","key":"10.1016\/j.biopha.2025.118730_bib68","doi-asserted-by":"crossref","first-page":"104367","DOI":"10.18632\/oncotarget.22248","article-title":"Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells","volume":"8","author":"D'Sousa Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118730_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jinorgbio.2019.01.011","article-title":"Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase","volume":"193","author":"Chen","year":"2019","journal-title":"J. Inorg. Biochem"},{"key":"10.1016\/j.biopha.2025.118730_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682968","article-title":"A novel ruthenium(II) complex with lapachol induces G2\/M phase arrest through Aurora-B kinase down-regulation and ROS-mediated apoptosis in human prostate adenocarcinoma cells","volume":"11","author":"De Grandis","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118730_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116909","article-title":"Novel tris-bipyridine based Ru(II) complexes as type-I\/-II photosensitizers for antitumor photodynamic therapy through ferroptosis and immunogenic cell death","volume":"279","author":"Zheng","year":"2024","journal-title":"Eur. J. Med Chem."},{"issue":"19","key":"10.1016\/j.biopha.2025.118730_bib72","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.3390\/ijms251910847","article-title":"Photodynamic therapy against colorectal cancer using porphin-loaded arene ruthenium cages","volume":"25","author":"Ghaddar","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118730_bib73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2005.01.002","article-title":"The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells","volume":"226","author":"Kapitza","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118730_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2017.07.009","article-title":"Sensitivity towards the GRP78 inhibitor KP1339\/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis","volume":"404","author":"Schoenhacker-Alte","year":"2017","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.biopha.2025.118730_bib75","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.3390\/cancers12092647","article-title":"Inhibition of DNA repair pathways and induction of ROS are potential mechanisms of action of the small molecule inhibitor BOLD-100 in breast cancer","volume":"12","author":"Bakewell","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.biopha.2025.118730_bib76","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.3390\/cancers14174126","article-title":"ER stress response and induction of apoptosis in malignant pleural mesothelioma: the achilles heel targeted by the anticancer ruthenium drug BOLD-100","volume":"14","author":"Ranzato","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib77","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41598-017-18639-6","article-title":"A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells","volume":"8","author":"Silva","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118730_bib78","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3390\/ijms19061609","article-title":"Ru(II)-thymine complex causes cell growth inhibition and induction of caspase-mediated apoptosis in human promyelocytic Leukemia HL-60 cells","volume":"19","author":"Oliveira","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acsomega.9b01921","article-title":"Nucleobase derivatives as building blocks to form Ru(II)-based complexes with high cytotoxicity","volume":"5","author":"Carvalho","year":"2020","journal-title":"ACS Omega"},{"issue":"38","key":"10.1016\/j.biopha.2025.118730_bib80","doi-asserted-by":"crossref","first-page":"16631","DOI":"10.1002\/anie.202006089","article-title":"Necroptosis induced by ruthenium(II) complexes as dual catalytic inhibitors of topoisomerase I\/II","volume":"59","author":"Xiong","year":"2020","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.biopha.2025.118730_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112230","article-title":"Synthesis, RNA-sequence and evaluation of anticancer efficacy of ruthenium(II) polypyridyl complexes toward HepG2 cells","volume":"244","author":"Hu","year":"2023","journal-title":"J. Inorg. Biochem"},{"issue":"89","key":"10.1016\/j.biopha.2025.118730_bib82","doi-asserted-by":"crossref","first-page":"13091","DOI":"10.1039\/D4CC04217D","article-title":"Ru(II) complex-based COX-2 targeting type I photosensitizer evokes ferroptosis and apoptosis","volume":"60","author":"Qi","year":"2024","journal-title":"Chem. Commun. (Camb. )"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib83","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41420-024-02033-z","article-title":"Necroptosis induced by ruthenium (II) complexes as mitochondrial disruptors","volume":"10","author":"Gon\u00e7alves","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2025.118730_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117059","article-title":"Ruthenium complex containing 1,3-thiazolidine-2-thione inhibits hepatic cancer stem cells by suppressing Akt\/mTOR signalling and leading to apoptotic and autophagic cell death","volume":"177","author":"Neves","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.118730_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500057","article-title":"Synthesis and structure of naphthoyl thiourea-based binuclear ruthenium(II) arene complexes: studies on anticancer activity and apoptotic mechanism","volume":"26","author":"Arunachalam","year":"2025","journal-title":"Chembiochem"},{"issue":"5","key":"10.1016\/j.biopha.2025.118730_bib86","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.7150\/ijbs.31143","article-title":"Construing the biochemical and molecular mechanism underlying the in vivo and in vitro chemotherapeutic efficacy of ruthenium-baicalein complex in colon cancer","volume":"15","author":"Wang","year":"2019","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118730_bib87","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fonc.2019.00582","article-title":"Ruthenium complexes with piplartine cause apoptosis through MAPK signaling by a p53-dependent pathway in human colon carcinoma cells and inhibit tumor development in a xenograft model","volume":"9","author":"Baliza","year":"2019","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47539-0","article-title":"Ru(II)-thymine complex causes DNA damage and apoptotic cell death in human colon carcinoma HCT116 cells mediated by JNK\/p38\/ERK1\/2 via a p53-independent signaling","volume":"9","author":"Silva","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47914-x","article-title":"Ruthenium(II) complexes with 6-methyl-2-thiouracil selectively reduce cell proliferation, cause DNA double-strand break and trigger caspase-mediated apoptosis through JNK\/p38 pathways in human acute promyelocytic leukemia cells","volume":"9","author":"Bomfim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118730_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fonc.2020.00141","article-title":"Combination of ruthenium complex and doxorubicin synergistically inhibits cancer cell growth by down-regulating PI3K\/AKT signaling pathway","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118730_bib91","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1021\/acsptsci.4c00020","article-title":"Insights into mechanisms and promising triple negative breast cancer therapeutic potential for a water-soluble ruthenium compound","volume":"7","author":"Nayeem","year":"2024","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.biopha.2025.118730_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2025.127680","article-title":"Exploring the chemotherapeutic potential of diosmetin ruthenium-p-cymene complex in bladder cancer treatment through the regulation of the PI3K\/\u03b2-catenin\/TJP1\/AR signaling pathway","volume":"90","author":"Sil","year":"2025","journal-title":"J. Trace Elem. Med Biol."},{"key":"10.1016\/j.biopha.2025.118730_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107985","article-title":"Cell plasticity, senescence, and quiescence in cancer stem cells: biological and therapeutic implications","volume":"231","author":"Paul","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118730_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102692","article-title":"Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells","volume":"62","author":"Costa","year":"2023","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118730_bib95","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s11095-016-2021-2","article-title":"A pH-sensitive nanocarrier for tumor targeting: delivery of ruthenium complex for tumor theranostic by pH-sensitive nanocapsule","volume":"33","author":"Chen","year":"2016","journal-title":"Pharm. Res"},{"issue":"36","key":"10.1016\/j.biopha.2025.118730_bib96","doi-asserted-by":"crossref","first-page":"60188","DOI":"10.18632\/oncotarget.19028","article-title":"Flexible ligated ruthenium(II) self-assemblies sensitizes glioma tumor initiating cells in vitro","volume":"8","author":"Elumalai","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2025.118730_bib97","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1039\/D2QI00423B","article-title":"Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity","volume":"9","author":"Marloye","year":"2022","journal-title":"Inorg. Chem. Front"},{"key":"10.1016\/j.biopha.2025.118730_bib98","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejmech.2018.07.048","article-title":"Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]2+ co-targeting drug resistant GRP78 and subcellular organelles in cancer stem cells","volume":"156","author":"Purushothaman","year":"2018","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118730_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115536","article-title":"Monofunctional dimetallic Ru(\u03b76-arene) complexes inhibit NOTCH1 signaling pathway and synergistically enhance anticancer effect in combination with cisplatin or vitamin C","volume":"258","author":"Wang","year":"2023","journal-title":"Eur. J. Med Chem."},{"issue":"40","key":"10.1016\/j.biopha.2025.118730_bib100","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1039\/D0CC00472C","article-title":"Inhibition of 3D colon cancer stem cell spheroids by cytotoxic RuII-p-cymene complexes of mesalazine derivatives","volume":"56","author":"Acharya","year":"2020","journal-title":"Chem. Commun. (Camb. )"},{"key":"10.1016\/j.biopha.2025.118730_bib101","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.actbio.2015.12.020","article-title":"Anti-metastatic effects of RAPTA-C conjugated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids","volume":"32","author":"Lu","year":"2016","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.biopha.2025.118730_bib102","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/acsabm.2c00556","article-title":"Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2\u2032,3\u2032-c]phenazine-Based Ru(II)\/Ir(III)\/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy","volume":"6","author":"Das","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"issue":"12","key":"10.1016\/j.biopha.2025.118730_bib103","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41419-023-06330-w","article-title":"New ruthenium-xanthoxylin complex eliminates colorectal cancer stem cells by targeting the heat shock protein 90 chaperone","volume":"14","author":"Santos","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib104","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41420-023-01759-6","article-title":"A novel ruthenium complex with 5-fluorouracil suppresses colorectal cancer stem cells by inhibiting Akt\/mTOR signaling","volume":"9","author":"Silva","year":"2023","journal-title":"Cell Death Discov."},{"issue":"13","key":"10.1016\/j.biopha.2025.118730_bib105","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1021\/acs.jmedchem.4c00406","article-title":"2-Aryl-1H-imidazo[4,5-f][1,10]phenanthroline-Based Binuclear Ru(II)\/Ir(III)\/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents","volume":"67","author":"Kar","year":"2024","journal-title":"J. Med Chem."},{"issue":"23","key":"10.1016\/j.biopha.2025.118730_bib106","doi-asserted-by":"crossref","first-page":"21470","DOI":"10.1021\/acs.jmedchem.4c02357","article-title":"A novel substituted benzo[g]quinoxaline-based cyclometalated Ru(II) complex as a biocompatible membrane-targeted PDT colon cancer stem cell agent","volume":"67","author":"Marco","year":"2024","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118730_bib107","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1039\/D2QI01079H","article-title":"A photoactive lysosome targeting RuII complex downregulates stemness genes in oral squamous cell carcinoma","volume":"9","author":"Roy","year":"2022","journal-title":"Inorg. Chem. Front"},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib108","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41420-024-02036-w","article-title":"Ru(II)-based complexes containing 2-thiouracil derivatives suppress liver cancer stem cells by targeting NF-\u03baB and Akt\/mTOR signaling","volume":"10","author":"Bomfim","year":"2024","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.118730_bib109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13046-023-02931-7","article-title":"Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy","volume":"43","author":"Alcal\u00e1","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118730_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118080","article-title":"Ru(II)-thymine complex suppresses acute myeloid leukemia stem cells by inhibiting NF-\u03baB signaling","volume":"187","author":"Oliveira","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118730_bib111","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/molecules23061471","article-title":"Poly(alkylidenimine) dendrimers functionalized with the organometallic moiety [Ru(\u03b7\u2075-C\u2085H\u2085)(PPh\u2083)\u2082]\u207a as promising drugs against Cisplatin-Resistant cancer cells and human mesenchymal stem cells","volume":"23","author":"Gouveia","year":"2018","journal-title":"Molecules"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:46:05Z","timestamp":1777013165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":111,"alternative-id":["S0753332225009242"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118730","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruthenium-based drugs as cancer stem cell inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118730"}}